Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients

Summary

This is a Phase I, open-label, parallel design study of PAN-301-1 (SNS-301), a HAAH directed nanoparticle vaccine, given intradermally in cohorts of patients with biochemically relapsed prostate cancer, using a fixed dose escalation schema every 21 days.

Timeline

Start

2016-12

Primary completion

2018-12

Completion

2018-12

Drugs

Indications